Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 4, 1999, Pages 439-442

  Legros, D ^a   Evans, S ^b   Maiso, F ^c   Enyaru, J C K ^d   Mbulamberi, D ^e  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c Natl Sleeping Sickness Contr Prog   (Uganda)

^d Livestock Health Research Institute Uganda   (Uganda)

^e MINISTRY OF HEALTH   (Uganda)

Author keywords

Chemotherapy; Melarsoprol; Treatment failure; Trypanosoma brucei gambiense; Trypanosomiasis; Uganda

Indexed keywords

MELARSOPROL;

ADOLESCENT; ADULT; AFRICAN TRYPANOSOMIASIS; ARTICLE; CEREBROSPINAL FLUID; CHILD; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TREATMENT FAILURE; TRYPANOSOMA; UGANDA;

EID: 0032871338     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90151-7     Document Type: Article

References (11)

1. Bouchet, B., Legros, D. & Lee, E. (1998). Key indicators for the monitoring and evaluation of control programs of human African trypanosomiasis due to Trypanosoma brucei gambiense. Tropical Medicine and International Health, 3, 474-481.
2. Burri, C., Baltz, T., Giroud, C., Doua, F., Welker, H. A. & Brun, R. (1993). Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy., 39, 225-234.
3. Doua, F. & Boa Yapo, F. (1993). Human trypanosomiasis in the Ivory Coast: therapy and problems. Acta Tropica, 54, 163-168.
4. Doua, F. & Boa Yapo, F. (1994). Actualités thérapeutiques de la trypanosomiase. Bulletin de la Société de Pathologie Exotique, 87, 337-340.
5. Mbulamberi, D. B. (1989a). A review of human African trypanosomiasis (HAT) in Uganda. East African Medical Journal, 66, 743-747.
6. Mbulamberi, D. B. (1989b). Possible causes leading to an epidemic outbreak of sleeping sickness: facts and hypotheses. Annales de la Société Belge de Médecine Tropicale, 69 (supplement 1), 173-179.
7. Milord, F., Pépin, J., Loko, L., Ethier, L. & Mpia, B. (1992). Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet, 340, 652-655.
8. Pépin, J. & Milord, F. (1994). The treatment of human African trypanosomiasis. Advances in Parasitology, 33, 1-47.
9. Pépin, J., Milord, F., Meurice, F., Ethier, L., Loko, L. & Mpia, B. (1992). High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene, 86 (supplement 3), 254-256.
10. Pépin, J., Milord, F., Khonde, A., Niyonsenga, T., Loko, L. & Mpia, B. (1994). Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88, 447-452.
11. van Nieuwenhove, S. (1992). Advances in sleeping sickness therapy. Annales de la Société Belge de Médecine Tropicale, 72 (supplement 1), 39-51.